Jejunal pouch for postoperative quality of life following Roux-en-Y reconstruction of radical total gastrectomy: a multicenter randomized controlled trial (WCGCC-1202)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003826

Enrollment

Unknown

Registered

2013-11-19

Start date

2014-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

A:Roux-en-Y reconstruction

B:Roux-en-Y+pouch reconstruction

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Preoperative endoscopy and biopsy confirmed gastric adenocarcinoma, and predictively feasible of total gastrectomy; 2. Predictively resectable diseases, either early or locally advanced gastric cancer, of preoperative staging JGCA 14th Edition cT1N0M0-T4aN3M0, I-IIIb, except T4b; 3. Aged 18 to 75 years; 4. Without serious disease; 5. WHO performance score <2; 6. No limit to sexual and race; 7. Informed consent required.

Exclusion criteria

Exclusion criteria: 1. Primary lesion cannot be resected in the pattern of transabdominal total gastrectomy, but for Whipple's procedure, or combined organ resection or with a transthoracic approach surgery; 2. Patients with other gastric malignant diseases, such as lymphoma and stromal tumors etc. 3. Patients suffering from malignant diseases before the study; 4. Patients with other severe comorbidities and cannot tolerate surgery: such as severe heart and lung diseases, heart function below clinical stage 2, uncontrollable hypertension, pulmonary infection, moderate to severe COPD, chronic bronchitis, severe diabetes and / or renal insufficiency, severe hepatitis and / or function below the rank of CHILD B grade, and severe malnutrition, etc. 5. Performed emergency operation due to bleeding or perforation; 6. Patients treated with neoadjuvant chemotherapy or radiation therapy which might affect the efficacy observation; 7. Not the radical surgery, but with tumor residual (R1 or R2).

Design outcomes

Primary

Measure	Time frame
EORTC QLQ-STO22;EORTC QLQ-C3;	—

Secondary

Measure	Time frame
Complication;the recurrence and transfer after the operaion;	—

Countries

China

Contacts

Public ContactJian-Kun Hu

Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, China

hujkwch@126.com+86 28 8542878

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026